Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Paragon Therapeutics

Tracked across 12 events · 640 articles · First seen Jul 21, 2025 · Last active Sep 23, 2026

Sentiment
13
Attention
6
Events
12
Relationships
34
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Regulatory
Impact: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
2 40
Business
Impact: Divests MTX652 to focus on CNS pipeline, receives up to $292M in payments.
Jul 17, 2026 · 6 articles
6 -90
Regulatory
Impact: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
4 -55
Regulatory
Paragon Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers are defendants in a securities fraud class action pending in the United States — United States District Court for the Southern District of California, captioned…
Impact: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
2 -40
Regulatory
Rosen Law Firm has filed a securities class action lawsuit against Paragon Therapeutics, Inc. on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor…
Impact: Capricor is the defendant in the securities class action, facing allegations of misleading investors regarding its Deramiocel BLA and statistical analysis plan changes. The lawsuit and upcoming lead plaintiff deadline could negatively affect its stock price and reputation.
Sep 21, 2026 · 6 articles
6 90
Tech
Impact: Paragon Therapeutics is a spinout company co-founded by Professor Stuart Forbes to commercialize the macrophage therapy. The company is currently testing a new version of the therapy, RTX001, in the EMERALD clinical trial, indicating significant progress and potential for future market impact.
May 25, 2026 · 7 articles
4 60
Business
Impact: Paragon Therapeutics, NicOx's exclusive licensee in China, received positive pre-submission regulatory feedback for NCX 470, allowing them to proceed with the New Drug Application submission in China. This is a significant step towards commercializing the drug in their licensed territories.
Jun 18, 2026 · 7 articles
4 70
Regulatory
Impact: Ocumension is the exclusive licensee in China and submitted the NDA. It has already invested €18 million in license fees and contributed to trial costs, positioning itself for a commercial launch and potential revenue from NCX 470 sales.
Aug 10, 2026 · 6 articles
2 20
Business
Impact: Ocumension holds licensing rights to NCX 470 for Chinese, Korean and Southeast Asian markets. Its regulatory progress contributes to NicOx's overall program value.
Sep 02, 2026 · 6 articles
4 -10
Regulatory
Impact: Capricor received a review extension for its Duchenne muscular dystrophy drug after an adverse advisory committee vote, adding uncertainty.
Aug 25, 2026 · 6 articles
4 0
Business
Impact: Altor BioScience was launched based on assets licensed from Paragon Therapeutics, indicating its foundational role in Altor BioScience' existence.
Jun 03, 2026 · 12 articles
3 0
Business
Impact: Glicko rating system was Chief Commercial Officer of Paragon Therapeutics.
Jun 09, 2026 · 6 articles
100 Paragon Therapeutics faced securities class actionCapricor Deramiocel...
95 Paragon Therapeutics faced securities fraud lawsuitCapricor Deramiocel...
95 Paragon Therapeutics sued for securities fraudCapricor Deramiocel...
95 Paragon Therapeutics sued for securities fraudCapricor Deramiocel...
90 Paragon Therapeutics changed statistical analysis planCapricor Deramiocel...
+ 69 more actions View on Dashboard
Medscape ↔ Paragon Therapeutics
Linda Marban ↔ Paragon Therapeutics
Medscape ↔ Paragon Therapeutics
Linda Marban ↔ Paragon Therapeutics
Cantor Fitzgerald ↔ Paragon Therapeutics
Cantor Fitzgerald ↔ Paragon Therapeutics
Bleichmar Fonti & Auld LLP ↔ Paragon Therapeutics
Bleichmar Fonti & Auld LLP ↔ Paragon Therapeutics
Schall Brown & Schwartz LLP ↔ Paragon Therapeutics
Schall Brown & Schwartz LLP ↔ Paragon Therapeutics
Kahn Swick & Foti ↔ Paragon Therapeutics
Kahn Swick & Foti ↔ Paragon Therapeutics
Hagens Berman ↔ Paragon Therapeutics
Hagens Berman ↔ Paragon Therapeutics
Glancy Prongay & Murray ↔ Paragon Therapeutics
Glancy Prongay & Murray ↔ Paragon Therapeutics
David Schwartz (disambiguation) ↔ Paragon Therapeutics
David Schwartz (disambiguation) ↔ Paragon Therapeutics
Kaplan Fox & Kilsheimer ↔ Paragon Therapeutics
Kaplan Fox & Kilsheimer ↔ Paragon Therapeutics
Lawrence Rosen ↔ Paragon Therapeutics
Philip Kim ↔ Paragon Therapeutics
Lawrence Rosen ↔ Paragon Therapeutics
Philip Kim ↔ Paragon Therapeutics
Rosen Law Firm ↔ Paragon Therapeutics
Rosen Law Firm ↔ Paragon Therapeutics
+ 4 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track Paragon Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.